FDA Clears IND Application for Micro-dystrophin Gene Therapy Program to Treat Duchenne – Muscular Dystrophy News
Muscular Dystrophy News |
FDA Clears IND Application for Micro-dystrophin Gene Therapy Program to Treat Duchenne
Muscular Dystrophy News The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a micro-dystrophin gene therapy program by Sarepta Therapeutics and Nationwide Children's Hospital, in clinical development for Duchenne muscular … |
